Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 451 to 465 of 868 results for score

  1. Cytosponge for detecting abnormal cells in the oesophagus (MIB240)

    NICE has developed a medtech innovation briefing (MIB) on Cytosponge for detecting abnormal cells in the oesophagus .

  2. Promoting health and preventing premature mortality in black, Asian and other minority ethnic groups (QS167)

    This quality standard covers promoting health and preventing premature mortality among black, Asian and other minority ethnic groups. It is relevant to all age groups and all settings.

  3. Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy (HST24)

    Evidence-based recommendations on onasemnogene abeparvovec (Zolgensma) for treating presymptomatic spinal muscular atrophy in babies aged 12 months and under.

  4. Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)

    Evidence-based recommendations on daratumumab (Darzalex) for relapsed and refractory multiple myeloma in adults.

  5. Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments (TA881)

    Evidence-based recommendations on ripretinib (Qinlock) for treating gastrointestinal stromal tumour in adults after 3 or more treatments.

  6. Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma in adults.

  7. Cochlear implants for children and adults with severe to profound deafness (TA566)

    Evidence-based recommendations on cochlear implants for children and adults with severe to profound deafness.

  8. Percutaneous electrothermal treatment of the intervertebral disc annulus for low back pain and sciatica (HTG398)

    Evidence-based recommendations on percutaneous electrothermal treatment of the intervertebral disc annulus for low back pain and sciatica. This involves delivering heat energy to the damaged disc annulus.

  9. Electrotherapy for the treatment of haemorrhoids (HTG377)

    Evidence-based recommendations on electrotherapy for treating grade I to III haemorrhoids in adults. This involves using electric current to shrink the haemorrhoids.

  10. Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation (HTG752)

    Evidence-based recommendations on transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation. This involves implanting a replacement valve inside the faulty native valve.

  11. Targeted muscle reinnervation for managing limb amputation pain (HTG750)

    Evidence-based recommendations on targeted muscle reinnervation for managing limb amputation pain. This involves attaching nerves that were cut during limb amputation to other nerves in nearby muscles.

  12. Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)

    Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making

  13. O2matic PRO 100 for optimising oxygen treatment in respiratory conditions (MIB308)

    NICE has developed a medtech innovation briefing (MIB) on O2matic PRO 100 for optimising oxygen treatment in respiratory conditions .

  14. Mepolizumab for treating severe eosinophilic asthma (TA671)

    Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults.

  15. Lumasiran for treating primary hyperoxaluria type 1 (HST25)

    Evidence-based recommendations on lumasiran (Oxlumo) for primary hyperoxaluria type 1 in people of all ages.